Sign in

    Insulet Corp (PODD)

    You might also like

    Insulet Corporation, headquartered in Massachusetts, is a medical device company focused on developing, manufacturing, and selling continuous insulin delivery systems for individuals with insulin-dependent diabetes. The company's primary product line is the Omnipod platform, which includes the Omnipod Insulin Management System, Omnipod DASH, and Omnipod 5 Automated Insulin Delivery System, all featuring a tubeless, wearable design for up to three days of continuous insulin delivery controlled via a smartphone or dedicated controller . Insulet also engages in the sale of a modified version of the Pod for drug delivery to pharmaceutical and biotechnology companies, and is expanding its offerings to include non-insulin subcutaneous drug delivery across other therapeutic areas .

    1. Omnipod Platform - Develops and sells a range of continuous insulin delivery systems, including the Omnipod Insulin Management System, Omnipod DASH, and Omnipod 5 Automated Insulin Delivery System, all designed for tubeless, wearable insulin delivery.
    2. Drug Delivery - Provides a modified version of the Pod to pharmaceutical and biotechnology companies for drug delivery applications.
    NamePositionStart DateShort Bio
    James R. HollingsheadPresident and Chief Executive OfficerJune 1, 2022James R. Hollingshead has been serving as the President and CEO of Insulet Corporation since June 1, 2022. He has been a member of the Board of Directors since July 2019. Previously, he was the President of the Sleep and Respiratory Care business at ResMed, Inc. .
    Lauren BuddenInterim Chief Financial Officer and Treasurer, Group Vice President, Chief Accounting Officer, and ControllerOctober 20, 2023Lauren Budden has been serving as the Interim CFO and Treasurer since October 20, 2023. She joined Insulet in April 2019 and has held various financial roles. She is a Certified Public Accountant with previous experience at Gulf Oil, Medtronic, and Covidien plc .
    Eric BenjaminExecutive Vice President, Chief Product and Customer Experience OfficerJuly 2023Eric Benjamin joined Insulet in 2015 and has served as the Chief Product and Customer Experience Officer since July 2023. He has held various roles within the company and previously worked at Abbott Laboratories .
    Laetitia CousinSenior Vice President, Regulatory Affairs, Quality Assurance and ComplianceDecember 2022Laetitia Cousin joined Insulet in 2022 and has been serving as the Senior Vice President, Regulatory Affairs, Quality Assurance and Compliance since December 2022. She has over 25 years of experience in the medical device industry .
    John KapplesSenior Vice President and General CounselMarch 2019John Kapples has served as the Senior Vice President and General Counsel at Insulet Corporation since March 2019. He previously held legal roles at GCP Applied Technologies, Inc., Medtronic plc, and Covidien .
    Dan ManeaSenior Vice President and Chief Human Resources OfficerMay 2020Dan Manea has been the Senior Vice President and Chief Human Resources Officer at Insulet Corporation since May 2020. He has extensive HR experience from his previous roles at Novartis and Eli Lilly .
    Prem SinghSenior Vice President, Global OperationsJanuary 2023Prem Singh joined Insulet in 2021 and has served as the Senior Vice President, Global Operations since January 2023. He has extensive experience in global operations and supply chain management from his previous roles at Thermo Fisher Scientific Inc. and General Electric .
    Ana Maria ChadwickExecutive Vice President, Chief Financial Officer, and TreasurerApril 22, 2024Ana Maria Chadwick was appointed as the Executive Vice President, Chief Financial Officer, and Treasurer of Insulet Corporation, effective April 22, 2024 .
    1. Given that over 85% of your U.S. new customer starts came from people previously on multiple daily injections (MDI), how do you plan to sustain this growth trajectory, and what strategies are in place to continue converting MDI users to Omnipod therapy in a market that may become increasingly saturated?

    2. With competitors entering the pharmacy channel and pushing on pricing, how confident are you in your ability to defend your pricing and margins in this channel, and what measures are you taking to mitigate potential pricing pressures from these competitors?

    3. You mentioned that retention rates among type 2 patients might be lower due to comorbidities and other factors; how do you plan to address potential retention challenges in the type 2 segment to ensure sustained growth and customer loyalty?

    4. As you expand internationally, particularly in Europe where patients are on longer contract cycles, what challenges do you anticipate in accelerating the adoption of Omnipod 5, and how will these contract structures impact your growth strategy and market penetration in these markets?

    5. While your customer service has scaled since the overwhelming demand at the launch of Omnipod 5, how are you ensuring that service quality remains high as you continue to grow rapidly, and what steps are you taking to prevent service issues from impacting patient satisfaction and retention?

    YearAmount Due (Millions)Debt TypeInterest Rate (%)% of Total Debt
    202442.0Current Portion of Long-Term DebtN/A3.0% = (42.0 / 1,398.3) * 100
    2026800.0Convertible Senior Notes0.37557.2% = (800.0 / 1,398.3) * 100
    2031475.2Term Loan BSOFR + 2.534.0% = (475.2 / 1,398.3) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Medtronic: A large, well-capitalized company with more resources than PODD, offering competitive advantages such as greater name recognition and established relations with healthcare professionals, customers, and third-party payors .
    • Tandem: Competes in the insulin pump market .
    • The Ypsomed Group: Competes in the insulin pump market .
    • Roche Diabetes Care, Inc ("Roche"): A large, well-capitalized company with more resources than PODD, offering competitive advantages such as greater name recognition and established relations with healthcare professionals, customers, and third-party payors .
    CustomerRelationshipSegmentDetails
    Distributor A
    Key distributor of Omnipod products
    All
    28% of total 2023 revenue (~$475.2M) out of $1,697.1M; 19% in 2022; 35% of net accounts receivable trade (~$82.1M) out of $234.5M.
    Distributor B
    Key distributor of Omnipod products
    All
    24% of total 2023 revenue (~$407.3M) out of $1,697.1M; 16% in 2022; 25% of net accounts receivable trade (~$58.6M) out of $234.5M.
    Distributor C
    Key distributor of Omnipod products
    All
    19% of total 2023 revenue (~$322.4M) out of $1,697.1M; 17% in 2022; 18% of net accounts receivable trade (~$42.2M) out of $234.5M.
    NameStart DateEnd DateReason for Change
    Grant Thornton LLPJune 16, 2016 PresentCurrent auditor.
    Ernst & Young LLPN/AJune 16, 2016 The change was made following a competitive process and approval by the Audit Committee.

    Recent developments and announcements about PODD.

    Financial Reporting

      Auditor Changes

      ·
      Jun 17, 2016, 12:00 AM

      Insulet Corporation Auditor Change

      On June 16, 2016, Insulet Corporation's Audit Committee appointed Grant Thornton LLP as the new independent registered public accounting firm, replacing Ernst & Young LLP. This change was effective immediately. There were no disagreements or reportable events with Ernst & Young during their tenure .